Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07430501Not Yet Recruiting

Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).

Role: collaborator

NCT07313358Not Yet Recruiting

10119473 -VIROMARKERS HDV Biomarkers Study

Role: collaborator

NCT06890039Phase 2Not Yet Recruiting

A-TANGO Phase 2 Study

Role: collaborator

NCT05651724Recruiting

Global Research Initiative for Patients Screening on MASH

Role: collaborator

All 4 trials loaded